Lucas V. Greder, Ph.D.
650-335-6117
lgreder@fenwick.com
Associate
Intellectual Property
Lucas V.
Greder, Ph.D.
Lucas V.
Greder, Ph.D.
Lucas V.
Greder, Ph.D.
Associate
Intellectual Property
Industries

Lucas advises on a wide range of intellectual property matters to support clients in the life sciences industry. In particular, he manages patent portfolios; drafts and prosecutes patent applications; and assists with due diligence, freedom-to-operate studies, landscape analysis, and patentability opinions. Lucas combines his deep industry and technical experience with his business and legal acumen to help startups and emerging companies achieve strategic IP protection. He has experience representing clients in the following areas:

  • Gene therapy (e.g., AAV capsid engineering, vector design, vector production)
  • Cell therapy (e.g., autologous, allogenic)
  • Synthetic biology (e.g., engineered gene circuits)
  • Spatial transcriptomics (e.g., in situ hybridization, in situ sequencing, or in situ apture)
  • Genomics (e.g., RNA-seq, DNA-seq, ATAC-seq, CHIP-seq)
  • Bioinformatic analysis (e.g., algorithm development, machine learning)
  • Minimal residual disease (MRD), liquid biopsy, and cfDNA/RNA methods
  • Next generation sequencing methods (e.g., library preparation, sequencing, sequence analysis)
  • Immunology (e.g., CAR-T, CAR-NK, engineered Tregs)
  • Vaccines (e.g., mRNA, inactivated vaccines, viral vector vaccines)
  • Antibodies (e.g., scFv, bispecific, diabodies, BiTEs, VHH, among others)
  • Single-cell sequencing and multi-omics (e.g., RNA, DNA, or RNA and DNA from single cell)
  • Functional genomics (e.g., whole genome screening with CRISPR/Cas9 libraries)
  • Gene editing (e.g., CRISPR/Cas9)

Prior to joining Fenwick, Lucas was a technology specialist at a leading, global intellectual property law firm where he focused on patent portfolio management, drafting and prosecuting U.S. and international patent applications, and conducting due diligence, freedom-to-operate studies, and patent landscape analysis.

Prior to working in patent law, Lucas was a research scientist at Vertex Pharmaceuticals. In this position, he served as a cell biologist leading therapeutic hypothesis testing in the kidney disease space using in vitro disease modeling, gene editing, and phenotypic screening. He also established a stem cell laboratory and on-boarded gene editing technologies at Vertex’s Abingdon (UK) research site.

Lucas received his DPhil (Ph.D.) in cell and molecular biology (medical sciences) at the University of Oxford’s Weatherall Institute of Molecular Medicine. As the Oxford-Sir David Weatherall Scholar, he investigated gene regulatory interactions governing the birth of hematopoietic stem cells during development at single cell resolution using transcriptomic and genomic profiling, functional genomics, stem cells, viral vectors, and gene editing, among other techniques.

While in law school, Lucas served as editor for the Mitchell Hamline Law Review and co-editor-in-chief for Cybaris®, an Intellectual Property Law Review.

Read more

  • Selected speaker, “Keystone Symposium on Hematopoiesis,” Keystone Symposium, Jan 2017
  • Selected speaker, “Profiling the Endothelial-to-Hematopoietic Transition,” Weizmann Institute of Science, Israel, The RUNX Transcription Factors in Development and Disease Conf., October 2015
  • Owens, D., Anselmi, G., Oudelaar, A. M., Downes, D., Cavallo, A., Harman, J., Schwessinger, R., Bucakci, A., Greder, L., Ornellas, S., Jeziorska, D., Telenius, J., Hughes, J. R., de Bruijn, M., 2021, Dynamic Runx1 chromatin boundaries affect gene expression in hematopoietic development, bioRxiv, preprint
  • Harland, L., Simon, C., Senft, A., Costello, I., Greder, L., Imaz-Rosshandler, I., Göttgens, B., Marioni, J., Bikoff, E., Porcher, C., de Bruijn, M., Robertson, E., 2021, The T-box transcription factor Eomesodermin governs haemogenic competence of yolk sac mesodermal progenitors, Nat. Cell. Bio. 23(1): 61-74
  • Owens, D., Caulder, A., Frontera, V., Harman, J., Allan, A., Greder, L., Codner, G., Hublitz, P., McHugh, P., Teboul, L., de Bruijn, M., 2019, Microhomologies are prevalent at Cas9-induced larger deletions, Nucleic Acids Res. 47(14): 7402-7417
  • Greder, L.V., Post, J., Dutton, J.R., 2016, Using Oct4:CreER lineage tracing to monitor endogenous Oct4 expression during reprogramming of fibroblasts to induced pluripotent stem cells (iPSCs), Methods in Molecular Biology 10, 7651_2016_198
  • Ye, L., Chang, Y.H., Xiong, Q., Zhang, P., Somasundaram, P., Lepley, M., Swingen, C., Su, L., Wendel, J.S., Guo, J., Jang, A., Rosenbush, D., Zhang, L., Greder, L., Dutton, J., Zhang, J., Kamp, T.J., Kaufman, D., Ge, Y., Zhang, J, 2014, Myocardial repair in a porcine model using tri-lineage cardiovascular cell populations derived from human induced pluripotent stem cells, Cell Stem Cell 15(6), 750-761
  • Banga, A., Greder, L.V., Dutton, J.R., Slack, J.M., 2014, Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist, Gene Therapy 21, 19-27.Greder, L.V., Gupta, S., Li, S., et al., 2012, Analysis of endogenous Oct4 activation during iPS cell reprogramming using an inducible Oct4 lineage label, Stem Cells 30 (11), 2596-601
  • Ye, L.*, Zhang, S.*, Greder, L.V., Dutton, J., Keirstead, S.A., et al., 2013, Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF, PLoS ONE 8(1), e53764. doi:10.1371/journal.pone.0053764
  • Sajini, A., Greder, L.V., Dutton, J.R., Slack, J.M., 2012, Loss of Oct4 expression during the development of murine embryoid bodies, Dev. Biol. 371, 170-79
  • Banga, A., Akinci, E., Greder, L.V., Dutton, J.R., Slack, J.M., 2012, In vivo reprogramming Sox9 positive cells in the liver to insulin secreting ducts, Proc. Natl. Acad. Sci. USA 109 (38), 15336-41
  • Akinci, E., Banga, A., Greder, L.V., Dutton, J.R., Slack, J.M., 2012, Reprogramming of pancreatic exocrine cells towards a beta cell character using Pdx1, Ngn3, and MafA, Biochem. J. 442, 539-50
  • Kudva, Y.C.*, Ohmine, S.*, Greder, L.V., et al., 2012, Transgene-free disease specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes, Stem Cells Translational Med. 1, 451-61
  • Lucas V. Greder, Note, What Do We Do Now? How the Elimination of the Best Mode Requirement Minimizes Adequate Disclosure and Creates a Potentially Unenforceable Fact Pattern, 3 Cybaris An Intell. Prop. L. Rev. 104 (2012)

  • Selected speaker, “Keystone Symposium on Hematopoiesis,” Keystone Symposium, Jan 2017
  • Selected speaker, “Profiling the Endothelial-to-Hematopoietic Transition,” Weizmann Institute of Science, Israel, The RUNX Transcription Factors in Development and Disease Conf., October 2015
  • Owens, D., Anselmi, G., Oudelaar, A. M., Downes, D., Cavallo, A., Harman, J., Schwessinger, R., Bucakci, A., Greder, L., Ornellas, S., Jeziorska, D., Telenius, J., Hughes, J. R., de Bruijn, M., 2021, Dynamic Runx1 chromatin boundaries affect gene expression in hematopoietic development, bioRxiv, preprint
  • Harland, L., Simon, C., Senft, A., Costello, I., Greder, L., Imaz-Rosshandler, I., Göttgens, B., Marioni, J., Bikoff, E., Porcher, C., de Bruijn, M., Robertson, E., 2021, The T-box transcription factor Eomesodermin governs haemogenic competence of yolk sac mesodermal progenitors, Nat. Cell. Bio. 23(1): 61-74
  • Owens, D., Caulder, A., Frontera, V., Harman, J., Allan, A., Greder, L., Codner, G., Hublitz, P., McHugh, P., Teboul, L., de Bruijn, M., 2019, Microhomologies are prevalent at Cas9-induced larger deletions, Nucleic Acids Res. 47(14): 7402-7417
  • Greder, L.V., Post, J., Dutton, J.R., 2016, Using Oct4:CreER lineage tracing to monitor endogenous Oct4 expression during reprogramming of fibroblasts to induced pluripotent stem cells (iPSCs), Methods in Molecular Biology 10, 7651_2016_198
  • Ye, L., Chang, Y.H., Xiong, Q., Zhang, P., Somasundaram, P., Lepley, M., Swingen, C., Su, L., Wendel, J.S., Guo, J., Jang, A., Rosenbush, D., Zhang, L., Greder, L., Dutton, J., Zhang, J., Kamp, T.J., Kaufman, D., Ge, Y., Zhang, J, 2014, Myocardial repair in a porcine model using tri-lineage cardiovascular cell populations derived from human induced pluripotent stem cells, Cell Stem Cell 15(6), 750-761
  • Banga, A., Greder, L.V., Dutton, J.R., Slack, J.M., 2014, Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist, Gene Therapy 21, 19-27.Greder, L.V., Gupta, S., Li, S., et al., 2012, Analysis of endogenous Oct4 activation during iPS cell reprogramming using an inducible Oct4 lineage label, Stem Cells 30 (11), 2596-601
  • Ye, L.*, Zhang, S.*, Greder, L.V., Dutton, J., Keirstead, S.A., et al., 2013, Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF, PLoS ONE 8(1), e53764. doi:10.1371/journal.pone.0053764
  • Sajini, A., Greder, L.V., Dutton, J.R., Slack, J.M., 2012, Loss of Oct4 expression during the development of murine embryoid bodies, Dev. Biol. 371, 170-79
  • Banga, A., Akinci, E., Greder, L.V., Dutton, J.R., Slack, J.M., 2012, In vivo reprogramming Sox9 positive cells in the liver to insulin secreting ducts, Proc. Natl. Acad. Sci. USA 109 (38), 15336-41
  • Akinci, E., Banga, A., Greder, L.V., Dutton, J.R., Slack, J.M., 2012, Reprogramming of pancreatic exocrine cells towards a beta cell character using Pdx1, Ngn3, and MafA, Biochem. J. 442, 539-50
  • Kudva, Y.C.*, Ohmine, S.*, Greder, L.V., et al., 2012, Transgene-free disease specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes, Stem Cells Translational Med. 1, 451-61
  • Lucas V. Greder, Note, What Do We Do Now? How the Elimination of the Best Mode Requirement Minimizes Adequate Disclosure and Creates a Potentially Unenforceable Fact Pattern, 3 Cybaris An Intell. Prop. L. Rev. 104 (2012)

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
Vertex Pharmaceuticals

Recipient of both Innovation and Achievement Awards

Green Templeton College

Recipient of the Oxford-Sir David Weatherall Scholarship awarded to the top international D. Phil (Ph.D.) candidate and recognized as a Clarendon Scholar

Recognition
Vertex Pharmaceuticals

Recipient of both Innovation and Achievement Awards

Green Templeton College

Recipient of the Oxford-Sir David Weatherall Scholarship awarded to the top international D. Phil (Ph.D.) candidate and recognized as a Clarendon Scholar

Login

Don’t have an account yet?

Register